One of the major challenges in developing effective in vitro-induced regulatory T cells (iTreg)-based cellular therapies is that the same inflammatory environment they are meant to suppress can also destabilize them.

The research group of Kelvin Chen, Tatsuya Kibayashi and Shimon Sakaguchi (Experimental Immunology, IFReC) discovered that deleting the transcription factor RBPJ in human CD4+ T cells enhances the differentiation, stability and functional capacity of iTreg.
(online publishing in Nature on March 27, 2025 JST)

Contact

Sakaguchi Lab

shimonifrec.osaka-u.ac.jp

Experimental Immunology